Last reviewed · How we verify
VM26
At a glance
| Generic name | VM26 |
|---|---|
| Sponsor | Johann Wolfgang Goethe University Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS (PHASE2)
- Teniposide Incorporating Bu/Cy Conditioning Regimen for HLH With Central Nervous System Involvemen (NA)
- Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia (PHASE4)
- German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99) (PHASE4)
- German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93) (PHASE4)
- Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma (PHASE2)
- Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia (PHASE2)
- Intensified Post Remission Therapy Containing PEG-Asparaginase (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |